Unknown

Dataset Information

0

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.


ABSTRACT: Therapeutic vaccination against chronic hepatitis B must overcome high viral antigen load and local regulatory mechanisms that promote immune-tolerance in the liver and curtail hepatitis B virus (HBV)-specific CD8 T cell immunity. Here, we report that therapeutic heterologous HBcore-protein-prime/Modified-Vaccinia-Virus-Ankara (MVA-HBcore) boost vaccination followed by CpG-application augmented vaccine-induced HBcAg-specific CD8 T cell-function in the liver. In HBV-transgenic as well as AAV-HBV-transduced mice with persistent high-level HBV-replication, the combination of therapeutic vaccination with subsequent CpG-application was synergistic to generate more potent HBV-specific CD8 T cell immunity that improved control of hepatocytes replicating HBV.

SUBMITTER: Kosinska AD 

PROVIDER: S-EPMC6658704 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7062423 | BioStudies
2020-01-01 | S-EPMC7521014 | BioStudies
2015-01-01 | S-EPMC4465460 | BioStudies
1000-01-01 | S-EPMC3618179 | BioStudies
2013-01-01 | S-EPMC3589400 | BioStudies
2015-01-01 | S-EPMC4351461 | BioStudies
2015-01-01 | S-EPMC4296901 | BioStudies
2014-01-01 | S-EPMC4105421 | BioStudies
2016-01-01 | S-EPMC4824405 | BioStudies
2020-01-01 | S-EPMC7118225 | BioStudies